ArticleCommunications biology2026
Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated omics reveal a unique antibacterial mechanism of action for the small molecule HSI#6.Current research in microbial sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a multidrug-resistant nosocomial pathogen responsible for infections that are often difficult to treat. Here, we show that exposure of A. baumannii to the last-resort antibiotic colistin, which disrupts the outer membrane of Gram-negative bacteria, results in inner membrane permeabilization and depolarization, ultimately inhibiting ATP synthesis. Nevertheless, under these conditions, colistin-resistant mutants are rapidly and frequently selected. In addition, A. baumannii is able to tolerate colistin, most likely due membrane depolarization and ATP depletion, which are hallmarks of antibiotic-tolerant subpopulations. In this context, we investigated whether bacteriocins can potentiate colistin activity. We identified and characterized two bacteriocins that inhibit the growth of multidrug-resistant clinical isolates, albeit at high concentrations. In vitro analyses showed that these small α-helical bacteriocins permeabilize phospholipid vesicles, highlighting their potential to potentiate antibiotics that compromise cell envelope integrity. Importantly, low concentrations of these bacteriocins combined with colistin leads to a substantial reduction in survival. Moreover, bacteriocin-colistin combinations limit the emergence of colistin-resistant mutants and partially restore susceptibility in colistin-resistant strains. These findings highlight the potential of combining bacteriocins and antibiotics to disrupt cell envelope homeostasis and support further evaluation of this strategy in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.